| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
70,670,000 |
| Market
Cap: |
151.23(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.8361 - $3.2 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ventyx Biosciences is a clinical-stage biopharmaceutical company engaged in the development of therapies for patients living with inflammatory diseases and autoimmune disorders. Co.'s product candidate is VTX958, an oral, selective clinical-stage tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis and Crohn's disease, among other potential indications. In addition, Co. is developing VTX002, an oral, selective sphingosine 1 phosphate receptor 1 modulator for ulcerative colitis. Co.'s oral, selective and peripherally restricted NLRP3 inhibitor, VTX2735, has been designed to treat systemic inflammatory diseases, such as cardiovascular, hepatic, renal and rheumatologic diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
630,000 |
630,000 |
| Total Buy Value |
$0 |
$0 |
$1,260,463 |
$1,260,463 |
| Total People Bought |
0 |
0 |
2 |
2 |
| Total Buy Transactions |
0 |
0 |
3 |
3 |
| Total Shares Sold |
1,887 |
1,887 |
36,167 |
3,337,040 |
| Total Sell Value |
$2,019 |
$2,019 |
$81,542 |
$46,221,061 |
| Total People Sold |
1 |
1 |
1 |
7 |
| Total Sell Transactions |
1 |
1 |
3 |
49 |
| End Date |
2025-03-30 |
2024-12-27 |
2024-06-28 |
2023-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Forman Mark S |
Chief Medical Officer |
• – – |
2025-05-15 |
4 |
A |
$1.03 |
$3,090 |
D/D |
3,000 |
3,000 |
|
- |
|
| Gonzales Roy |
Senior VP, Finance |
• – – |
2025-05-15 |
4 |
A |
$1.03 |
$1,803 |
D/D |
1,750 |
3,546 |
|
- |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2025-04-02 |
4 |
S |
$1.07 |
$2,019 |
D/D |
(1,887) |
467,226 |
|
-121% |
|
| Subramaniam Somu |
|
– • – |
2025-03-28 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,335,450) |
4,032,213 |
|
- |
|
| Mohan Raju |
CEO AND PRESIDENT |
• • – |
2025-03-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,844 |
2,303,540 |
|
- |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2025-03-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,531 |
469,113 |
|
- |
|
| Subramaniam Somu |
|
– • – |
2025-03-10 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,735,306) |
5,367,663 |
|
- |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-12-27 |
4 |
S |
$2.36 |
$49,841 |
D/D |
(21,119) |
464,582 |
|
48% |
|
| Gujrathi Sheila |
|
– • – |
2024-12-23 |
4 |
B |
$2.31 |
$300,573 |
I/I |
130,000 |
130,000 |
0.01 |
-49% |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-12-19 |
4 |
S |
$2.26 |
$29,682 |
D/D |
(13,161) |
485,701 |
|
36% |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,930 |
498,862 |
|
- |
|
| Mohan Raju |
CEO AND PRESIDENT |
• • – |
2024-12-17 |
4 |
OE |
$0.00 |
$0 |
D/D |
116,668 |
2,291,696 |
|
- |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-12-10 |
4 |
OE |
$0.20 |
$39,787 |
D/D |
198,934 |
463,932 |
|
- |
|
| Mohan Raju |
CEO AND PRESIDENT |
• • – |
2024-11-25 |
4 |
B |
$2.01 |
$524,944 |
D/D |
261,752 |
2,175,028 |
0.01 |
-56% |
|
| Mohan Raju |
CEO AND PRESIDENT |
• • – |
2024-11-22 |
4 |
B |
$1.83 |
$434,946 |
D/D |
238,248 |
1,913,276 |
0.01 |
-55% |
|
| Gonzales Roy |
Senior VP, Finance |
• – – |
2024-08-30 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
743 |
|
-7% |
|
| Subramaniam Somu |
|
– • • |
2024-06-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(641,327) |
7,102,969 |
|
- |
|
| Nsv Partners Iii Gp Llc |
10% Owner |
– – • |
2024-06-24 |
4 |
D |
$0.00 |
$0 |
I/I |
(641,327) |
7,102,969 |
|
- |
|
| Mohan Raju |
CEO AND PRESIDENT |
• • – |
2024-06-10 |
4 |
OE |
$0.20 |
$19,356 |
D/D |
96,778 |
1,675,028 |
|
- |
|
| Subramaniam Somu |
|
– • • |
2024-04-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(695,339) |
7,744,296 |
|
- |
|
| Nsv Partners Iii Gp Llc |
10% Owner |
– – • |
2024-04-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(695,339) |
7,744,296 |
|
- |
|
| Mohan Raju |
CEO AND PRESIDENT |
• • – |
2024-04-02 |
4 |
S |
$5.40 |
$23,299 |
D/D |
(4,312) |
1,578,250 |
|
63% |
|
| Auster Martin |
CHIEF FINANCIAL OFFICER |
• – – |
2024-04-02 |
4 |
S |
$5.40 |
$7,592 |
D/D |
(1,405) |
24,303 |
|
63% |
|
| Nuss John |
CHIEF SCIENTIFIC OFFICER |
• – – |
2024-04-02 |
4 |
S |
$5.40 |
$8,921 |
D/D |
(1,651) |
264,998 |
|
63% |
|
| Krueger Christopher W |
CHIEF BUSINESS OFFICER |
• – – |
2024-04-02 |
4 |
S |
$5.40 |
$8,921 |
D/D |
(1,651) |
284,999 |
|
63% |
|
197 Records found
|
|
Page 1 of 8 |
|
|
0.20 (8.55%) 
